ArticleCancer medicine2023
Survival trends for patients with retinoblastoma between 2000 and 2018: What has changed?
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Retinoblastoma research trends from 1980 to 2023: a 44-year bibliometric study.Frontiers in oncology · 2025Pooled it
- Provider and caregiver perspectives on vision services for childhood cancer survivors: a qualitative study.BMC health services research · 2026Article
- Cross-national inequalities and public health policy effects of the global retinoblastoma burden from 1990 to 2021 and projections to 2035.Frontiers in public health · 2026Article
- Comprehensive molecular analysis of uveal melanoma identifies targets in tumor-intrinsic and tumor-extrinsic pathways.iScience · 2025Article
- Retinoblastoma survival trend: a 30-year analysis from a referral single center in Iran.International journal of retina and vitreous · 2025Article
- USP33 Facilitates Retinoblastoma Growth by Deubiquitinating and Stabilizing EPHB2 Protein.Applied biochemistry and biotechnology · 2025Article
- Fatigue, anxiety and depression in parents of children with retinoblastoma: a cohort study.Translational pediatrics · 2025Article
- Prediction of mortality in patients with retinoblastoma based on random survival forest: a retrospective cohort analysis using SEER database.Translational cancer research · 2025Article
- Global, regional and national burden due to retinoblastoma in children aged younger than 10 years from 1990 to 2021.BMC medicine · 2024Article
- Multimodal imaging for the differential diagnosis and efficacy evaluation of intraocular retinoblastoma in children with selective ophthalmic artery infusion.Translational pediatrics · 2024Article
- Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA.Endocrine connections · 2023Article
- Survival trends for patients with retinoblastoma between 2000 and 2018: What has changed?Cancer medicine · 2023Article
- Epidemiological aspect of retinoblastoma in the world: a review of recent advance studies.International journal of ophthalmology · 2023Review
- Evolving trends in retinoblastoma management: A 16-year clinicopathological analysis of enucleated eyes.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRetinoblastoma (RB) is the most common primary intraocular cancer of childhood. Over the last few decades, a variety of techniques and treatment modalities emerged that improved the survival and ocular salvage rate of patients with RB. We investigated the relative survival trends of patients with RB from 2000 to 2018 by using the Surveillance, Epidemiology, and End Results (SEER) database.
designRetrospective database review.
methodsWe extracted data from SEER 18 from 2000 to 2018. All patients with clinically diagnosed RB during the study period were included. We utilized SEER*Stat 8.3.9 and JPSurv software to estimate relative 5- and 10-year survival rates and trends and generated descriptive analyses with IBM SPSS.
main outcome measuresPatient survival rates at 5- and 10-year after RB diagnosis.
resultsRB was diagnosed in 1479 patients within the SEER 18 Program during our study period. The cohort comprised 776 (52.5%) males, 615 (41.6%) non-Hispanic whites, 487(32.9%) Hispanics, 1030 (69.6%) patients with unilateral disease, and 1087 (73.5%) patients with localized disease. Relative survival trends at 5- and 10-year significantly declined over the study periods (-0.42%, and -0.50% annually, respectively) but the decline was not significant in unilateral and bilateral RB cases separately.
conclusionsFive- and ten-year relative survival trends declined from 2000 to 2018 and were significantly decreasing. Further studies that include more patients are needed to identify the factors contributing to reduced survival of patients with RB over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.